Introduction {#ns1}
============

Coronary artery disease (CAD) is the consequence of atherosclerotic plaque disposition on the coronary artery wall. Its manifestation depends on interactions between environmental and genetic risk factors ([@Andreassietal2003]). Individual susceptibility to the disease has been associated with functional allelic variation. Thus, the identification of gene polymorphisms relating to the formation of atherosclerotic plaques, and consequently, thrombi, may contribute towards developing early diagnostic methods and guiding preventive procedures ([@Arrudaetal1998]; [@Doevendansetal2001]; [@Andreassietal2003]). The gene that encodes methylene tetrahydrofolatereductase enzyme (MTHFR), which is involved in the metabolism of homocysteine (Hcy), is of great interest in clinical practice ([@Robinsonetal1995]; [@Hofmannetal2001]; [@Andreassietal2003]). Hcy, an amino acid derived from protein catabolism, is present in the plasma in several forms, with the greatest proportion (70%) bound to albumin ([@Doevendansetal2001]). High levels of Hcy (hyperhomocysteinemia) have been identified as a risk factor for atherosclerosis ([@Bovaetal1999]; [@HankeyandEikelboom1999]; [@Loboetal1999]; [@Doevendansetal2001]; [@Andreassietal2003]). The mechanism for the vascular lesions induced by hyperhomocysteinemia remains unclear. Experimental evidence suggests that Hcy facilitates the vascular oxidative process, thereby altering the coagulation system, and reduces the vasomotor regulation of the endothelium ([@Welchetal1997]; [@Tyagi1998]; [@HankeyandEikelboom1999]; [@Hofmannetal2001]). The aim of this study was to assess the relationship between MTHFR gene polymorphism and plasma homocysteine level with the traditional risk factors of coronary artery disease in a north Indian population.

Material and Methods {#ns2}
====================

Study subjects {#ns2.1}
--------------

Patients, with evidence of more than 50% stenosis in coronary arteries, a past history of prior angioplasty, or CAD by-pass grafting, were included in the present study. The patients were recruited from the outpatient and inpatient services of the Department of Cardiology, SGPGIMS during the period February, 2006 to November, 2008. The study group included angiographically proven CAD patients. The control group consisted of individuals without a CAD background and with negative results in treadmill-stress tests. The two groups were age and sex matched. An individual clinical background entailing the presence of diabetes, hypertension, smoking habits, CAD family history, body-mass index and complete lipid profile (serum triglycerides, total cholesterol, HDL, LDL and VLDL) were furnished by members of both the patient and control groups independently. Diabetes and hypertension was diagnosed in patients and controls, based on prior medical records or standard clinical examination and tests, according to the standard definition described by [@Faucietal2008]. Habitual smoking was defined as prevailing at least one year before CAD onset. A family history of CAD was defined based on its presence in first-degree relatives. Body-mass index was calculated by dividing the weight in kilograms by the square of the height in meters (Fouci *et al.*, 2008). Patients and controls included in the study were natives of Uttar Pradesh. Exclusion criteria were cardiomyopathy, a febrile condition, rheumatic heart disease, congenital heart disease and systemic disorders. A prior written informed consent was obtained from patients and controls. The study was approved by an institutional ethics committee.

DNA preparation and genotyping {#ns2.2}
------------------------------

Genomic DNA was extracted from EDTA peripheral blood leukocytes by the standard phenol-chloroform method ([@Ponczetal1982]). The quality of DNA was checked through 0.8% agarose (Sigma, USA) gel electrophoresis, and quantification was done on a UV spectrophotometer (Specgene Ltd, UK). Synthetic oligonucleotides were acquired from Genetix, France. Primers (Forward 5\'TGA AGG AGA AGG TGT CTG CGG GA3\', Reverse 5\'AGG ACG GTG CGG TGA GAG TG3\') for exon 4 of the MTHFR gene were used as described by Frost *et al.* (1995). Amplification was done in an automated thermocycler (BioRad PTC100, USA). The mixture was initially denatured at 94 °C for 4 min, followed by 30 cycles with 30 s at 94 °C, 45 s at 62 °C, 45 s at 72 °C and a 12 min final extension at 72 °C. PCR products were checked on 2% of agarose gels followed by staining with 1 μg/mL of ethidium bromide. . The amplified PCR products of 198 bp were digested with *Hinf*I (NEB UK) restriction enzyme according to manufacturer\'s specifications. The restriction digestion products were separated on a 3% agarose gel and visualized by ethidium bromide staining ([Figure 1](#fig1){ref-type="fig"}).

Biochemical analyses {#ns2.3}
--------------------

Fasting venous blood from patients and controls were collected in plain vials in order to analyze triglyceride (TG) levels. These levels were measured by lipoprotein lipase-peroxidase (Fossati and Prencipe*,* 1982), those of total cholesterol (TC) by cholesterol oxidase ([@Allainetal1974]) and those of high density lipoprotein (HDL) by phosphotungstate magnesium chloride methodology ([@Lopes-Virellaetal1977]). Very low density lipoprotein (VLDL) and low density lipoprotein (LDL) levels were calculated indirectly by means of the Friedwald formula ([@Friedewaldetal1972]) as (VLDL-C = TG/5 provided TG = 400 mg/dL) and LDL-C = TC -- (HDL-C + VLDL-C). Total plasma homocysteine levels were determined in 87 patients and 79 controls by enzyme linked immunoassay (Microplate EIA Homocysteine BioRad, USA). The assay method was based on enzymatic conversion of homocysteine to S-adenosyl homocysteine, followed by quantification of S-adenosyl-L-homocysteine by an enzyme- linked immunoassay ([@Frantzenetal1998]).

Statistical analysis {#ns2.4}
--------------------

Genotype and allele frequencies in CAD and control groups were compared by Chi square testing. The characteristics of patients and controls were evaluated by comparing biochemical findings using the Student t-test. Additionally, we performed multiple logistic regression model testing on the interaction of genotype and different classical CAD risk factors. All analyses were performed using SPSS v.11.5 (SPSS Inc., Chicago, USA) statistical analysis software. A two-tailed p value of p \< 0.05 was considered statistically significant.

Results {#ns3}
=======

The study group included 329 angiographically proven CAD patients \[80 with myocardial infarction (MI), and the remaining 249 with no past reference\], and 331 individuals as controls with no clinical history of CAD. The clinical and demographic data of patients and controls are presented in [Table 1](#t1){ref-type="table"}. Classical risk factors, viz., diabetes, hypertension, smoking and family history were significantly higher in the CAD group than in the control. The value of HDL- cholesterol was significantly lower in CAD patients than in controls, although serum triglyceride, total cholesterol, LDL-cholesterol, VLDL-cholesterol and homocysteine levels were found to be significantly higher in the former.

Allele and genotype frequencies in both patient and control group are described in [Table 2](#t2){ref-type="table"}. The distribution of genotypes within each group was in Hardy-Weinberg equilibrium. We found the prevalence of the CT genotype to be 11.5% in the control and 18.2% in the patient group, whereas almost similar mutant homozygous frequencies (1.5% and 2.8%) were observed in controls and patients, respectively. T allele frequency was significantly higher in the patient group (11.9%) than the control (7.3%) (p = 0.004, OR 1.75 95% CI 1.16-2.55). On compiling a subgroup of MI and non-MI patients, we found that 63 out of 80 MI patients (78.6%) presented a CC genotype, 13 (16.25%) a CT genotype, and 4 (5.0%) were homozygous for the T allele (TT genotype). C and T allele frequencies were 87% \[139\] and 13% \[21\], respectively, in the MI patient group. This indicates a significant association of the T allele with myocardial infarction in patients in contrast to control \[p = 0.016 (Fisher exact), OR 1.93 (95% CI 1.08-3.44)\].

When we assessed the severity of the disease in terms of the number of vessels involved in CAD and MTHFR polymorphism, interestingly we found no variation in T allele prevalence in either one, two or three vessels \[12.7%, 10.0% and 11.0%, respectively\] with stenosis in a CAD patient. Similarly findings were observed with homocysteine levels ([Table 3](#t3){ref-type="table"}). Significantly high levels of homocysteine were observed in the patient group as compared to the control, irrespective of the genotypes involved (CC, CT and TT) ([Table 3](#t3){ref-type="table"}).

On performing multiple logistic regression analysis; to see the influence of various risk factors on CAD precipitation ([Table 4](#t4){ref-type="table"}), we found that, in the case of diabetes, hypertension, smoking, triglyceride and HDL-cholesterol, this was significantly variable for CAD. We additionally observed that an increase to 10 mg/dL in Triglyceride, Total cholesterol and LDL-cholesterol, will increase the risk of CAD by 1.3 times, 1.01 times and 1.08 times, respectively, whereas a 10 mg/dL decrease in HDL-cholesterol leads to a 2.5 times greater risk of CAD. This indicates that HDL-C is more crucial for CAD. Furthermore a concurrent increase in MTHFR CT and TT genotypes leads to an even greater CAD risk (1.3 times and 1.2 times, respectively) than CC genotype.

Discussion {#ns4}
==========

The implication of the MTHFR gene in CAD pathogenesis has been extensively studied in several ethnic groups. We found a significantly higher frequency of T alleles in CAD patients than in controls. OR in this group was 1.75. Other epidemiological studies that estimated the risk of CAD associated with the T allele showed conflicting results. Notwithstanding, [@Kerkenietal2006] and [@Alametal2008] found this substitution to be a significant risk factor. On summarizing the results from 8 studies, [@Kluijtmansetal1996] encountered no significant difference for the T allele, although they reported higher frequencies (31.8% and 29% in patient and control group respectively).

We found the T allele to be significantly associated with myocardial infarction (p = 0.016, OR1.93, 95% CI 1.08-3.44). This finding is consistent with a previous report (Gülec *et al.*, 2001) in which MTHFR C677T transition was found to be a risk factor for premature MI. On the other hand, other authors ( [@Andersonetal1997]; [@Hsuetal2001]) reported insignificant differences for the T allele between MI subjects and the control group. We observed almost equal frequencies for the CC, CT and TT genotypes, irrespective of one-, two- or three-vessel-stenosis, Our findings are in accordance with previous reports ([@VanBockxmeeretal1997]; [@Kerkenietal2006]; [@Rassouletal2008]), in which insignificant association was observed. Nevertheless, for [@Moritaetal1997] the association was significant. Furthermore, we noted that the severity of the disease is independent of homocysteine levels. Likewise, [@Wangetal1999] found no correlation between the level of homocysteine and severity of the disease, whereas [@Rassouletal2008], on the contrary, discovered a positive association.

In our study, the average homocysteine level was significantly higher in the patient group than in the control. This is in agreement with observations by other investigators ([@Evansetal1997]; [@Kerkenietal2006]). The finding of a significant correlation between 5,10 methylene tetrahydrofolate reductase enzyme activity and MTHFR genotypes ([@Frosstetal1995]) (70% reduced activity in the TT genotype and 35% reduced activity in the CT genotype) implies elevated homocysteine levels in these two genotypes.

A previous study by [@Alametal2008] on 100 coronary artery cases and 100 controls, also from North India, demonstrated the positive association of MTHFR (C677T) gene polymorphism. The present study is in agreement, although with a larger-sized sample, and undertaken with certain restrictions, such as using a single MTHFR genetic marker (C677T). Thus, further polymorphic MTHFR markers need to be evaluated, together with the other genetic markers involved in the Homocysteine pathway for predisposition to the disease.

Coronary artery disease is a complex disorder where environmental and genetic markers both play an important role.

![Detection of MTHFR polymorphism. Lanes 2, 3, 5 and 6 showing wild type (CC) genotype, lane 1 showing mutant heterozygous (CT) genotype and lane 4 showing mutant homozygous (TT) genotype, M showing molecular weight Marker.](gmb-33-2-224-gfig1){#fig1}
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###### 

Characteristics of controls and patients.

  Characteristics                                    Controls           CAD Patients       p-value
  -------------------------------------------------- ------------------ ------------------ -----------
  N                                                  331                329                \-
  Age                                                53.18 ± 9.18\*     57.09 ± 9.66\*     0.217
  Sex (M:F)                                          245:86             260:69             0.142
  BMI                                                25.12 ± 3.12\*     25.54 ± 2.97\*     0.077
  Diabetic: nondiabetic                              82:249             142:187            0.000
  Hypertensive: nonhypertensive                      76:255             156:173            0.000
  Smoker: nonsmoker                                  33:299             66:263             0.000
  Positive family history: negative family history   04:329             13:316             0.028\*\*
  Triglyceride (45-150 mg/dL)                        95.75 ± 27.95\*    165.04 ± 81.33\*   0.000
  Total Cholesterol (125-250 mg/dL)                  154.70 ± 39.73\*   170.29 ± 48.56\*   0.000
  HDL-cholesterol (23-60 mg/dL)                      38.34 ± 7.79\*     36.51 ± 7.01\*     0.002
  LDL-cholesterol (92-148 mg/dL)                     97.82 ± 31.72\*    103.99 ± 43.67\*   0.039
  VLDL-cholesterol (10-30 mg/dL)                     19.59 ± 6.65\*     29.80 ± 13.90\*    0.000
  Homocysteine (5-15 μM/L)                           11.11 ± 4.39       16.05 ± 8.51       0.000

\*Mean ± SD, \*\* p-value (Yates correction).

###### 

Distribution of genotype and allele frequencies in patients and controls.

  Genotype/Allele   Control (N = 331)   Patient (N = 329)   OR     p-value   95% CI
  ----------------- ------------------- ------------------- ------ --------- -----------
  CC                288 (87.0%)         260 (79.0%)                          
  CT                38 (11.5%)          60 (18.20%)                0.054     
  TT                5 (1.5%)            9 (2.8%)                             
  C allele          614 (92.7%)         580 (88.1%)         1.75   0.004     1.16-2.55
  T allele          48 (7.3%)           72 (11.9%)                           

###### 

Plasma homocysteine levels in patients and controls.

                Homocysteine level\* controls (N = 79)   Homocysteine level\* patients (N = 87)   p-value
  ------------- ---------------------------------------- ---------------------------------------- ---------
  CC Genotype   11.86 ± 3.88 (66)                        14.42 ± 8.62 (56)                        0.000
  CT Genotype   11.094 ± 7.11 (9)                        18.64 ± 7.06 (25)                        0.000
  TT Genotype   16.1788 ± 3.96 (4)                       20.59 ± 10.07 (6)                        0.000
  1 vessel      \-                                       17.60 ± 9.47 (32)                        
  2 vessel      \-                                       15.15 ± 6.56 (21)                        0.437
  3 vessel      \-                                       15.15 ± 8.63 (34)                        

\*Values in (Mean ± SD); () number.

###### 

Multivariable logistic regression analysis between controls and patients.

  Variable            B        p-value   OR      95% CI
  ------------------- -------- --------- ------- ---------------
  BMI                 0.049    0.168     1.050   0.980-1.125
  Diabetes            0.844    0.000     2.326   1.480-3.655
  Hypertension        0.923    0.000     2.490   1.589-3.901
  Smoking             0.713    0.017     2.040   1.136-3.664
  Family history      1.004    0.172     2.728   0.649-11.45
  Triglyceride        0.033    0.000     1.034   1.021-1.05
  Total cholesterol   0.002    0.796     1.002   0.984-1.021
  HDL-cholesterol     -0.110   0.000     0.895   0.861-0.931
  LDL-cholesterol     0.011    0.260     1.011   0.992-1.031
  VLDL-cholesterol    -0.022   0.450     0.979   0.926-1.035
  MTHFR CT genotype   0.295    0.319     1.343   0.752-2.396
  MTHFR TT genotype   0.236    0.751     1.226   0\. 295-5.423
